[The role of slow-release 5-fluorouracil implantation in treatment of unresectable pancreatic cancer].
OBJECTIVE
To study the role of slow-release 5-fluorouracil implantation in treatment of unresectable pancreatic cancer.


METHODS
85 cases of untreated patients with locally advanced pancreatic cancer (LAPC) were randomized into two groups: Trial group: slow-release 5-fluorouracil implantation (50 patients) and control group (35 patients). Observing the objective tumor response, clinical benefit response, toxicity, complications and survival of patients of the two groups.


RESULTS
In the trial group the overall response rate (PR + NC) was 76.0%, and the clinical benefit response rate was 52.0%. No toxicity was observed. Pancreatic fistula occurred in 2 patients. The median survival time of the two groups was 9.0 months and 4.0 months, respectively. The survival rates of 6- and 12-month were 56.8% vs. 31.4% and 22.9% vs. 2.9% in the two groups, respectively (P = 0.012).


CONCLUSIONS
Slow-release 5-fluorouracil implantation is a simple, safe and effective method in treatment of LAPC.
Department of Abdominal Surgical Oncology, Cancer Hospital, Chineses Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Cheng-feng
CF
Wang
Ping
P
Zhao
Yi
Y
Shan
Dong-bing
DB
Zhao
Yan-tao
YT
Tian
Xiao-feng
XF
Bai
Yue-min
YM
Sun
Xu
X
Che
Hui
H
Qu
Yi-bin
YB
Xie
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000627:therapeutic use; D004343:Drug Implants / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008863:Microspheres; D008875:Middle Aged; D009367:Neoplasm Staging; D010185:Pancreatic Fistula / Q000209:etiology; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011446:Prospective Studies; D012074:Remission Induction; D015996:Survival Rate
D000964:Antimetabolites, Antineoplastic; D004343:Drug Implants; D005472:Fluorouracil